



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



BD-1047 dihydrobromide

Cat. No.:	HY-16996A
CAS No.:	138356-21-5
Molecular Formula:	C ₁₃ H ₂₂ Br ₂ Cl ₂ N ₂
Molecular Weight:	437.04
Target:	Sigma Receptor
Pathway:	Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (57.20 mM; Need ultrasonic)				
	H ₂ O : 25 mg/mL (57.20 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent Concentration Mass	1 mg	5 mg	10 mg
		1 mM	2.2881 mL	11.4406 mL	22.8812 mL
		5 mM	0.4576 mL	2.2881 mL	4.5762 mL
10 mM		0.2288 mL	1.1441 mL	2.2881 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: PBS Solubility: 33.33 mg/mL (76.26 mM); Clear solution; Need ultrasonic				
	2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.72 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.72 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	BD-1047 (dihydrobromide) is a selective functional antagonist of sigma-1 receptor, shows antipsychotic activity in animal models predictive of efficacy in schizophrenia ^[1] .
IC ₅₀ & Target	Sigma 1 Receptor
In Vitro	BD-1047 (dihydrobromide) prevents that Cutamesine reduces the cell death rate induced by light exposure in murine photoreceptor-derived 661w cells ^[2] . BD-1047 (dihydrobromide) attenuates that Cutamesine reduces the mitochondrial damage and the elevated level of

caspase 3/7 activity^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BD-1047 (dihydrobromide) (1-10 mg/kg; i.p.) decreases the Apomorphine (APO)-induced climbing behavior at the dose of 10 mg/kg in mice^[1].

?BD-1047 (dihydrobromide) counteracts the antidepressant-like effect induced by co-administration of pramipexole and sertraline (but not pramipexole and fluoxetine)^[3].

?BD-1047 (dihydrobromide) reduces the increasing expression of pNR1, and reverses the Sig-1 R agonists potentiated NMDA-induced pain behaviour and pNR1 immunoreactivity^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Albino Swiss mice (50 days old, 25–28 g) ^[1]
Dosage:	1 mg/kg, 3 mg/kg, 10 mg/kg
Administration:	Intraperitoneal injection
Result:	Decreased the APO-induced climbing at the dose of 10 mg/kg in mice.

CUSTOMER VALIDATION

- Cell Rep. 2023 Jan 31;42(1):112011.
- Mol Med. 2022 Aug 3;28(1):87.
- Int Immunopharmacol. 2023 Dec 22;127:111382.
- Int Immunopharmacol. 2023 Feb 22;117:109907.
- Eur J Pharmacol. 2023 Mar 8;175647.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Skuza G, et al. Effect of BD 1047, a sigma1 receptor antagonist, in the animal models predictive of antipsychotic activity. Pharmacol Rep. 2006 Sep-Oct;58(5):626-635.

[2]. Shimazawa M, et al. Effect of a sigma-1 receptor agonist, cutamesine dihydrochloride (SA4503), on photoreceptor cell death against light-induced damage. Exp Eye Res. 2015 Mar;132:64-72.

[3]. Rogó Z, et al. Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats. Pharmacol Rep. 2006 Jul-Aug;58(4):493-500.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA